# US 2021/0275616 A1 · Composition for ameliorating peripheral sensory neuropathy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275616 A1
- Document ID: US20210275616A1
- Status: Published application
- Kind: A1
- Application number: 17/328,401
- Filed: 2021-05-24
- Published: 2021-09-09
- Earliest claimed: 2016-12-20
- Assignees: Kinki University; Kobayashi Pharmaceutical Co., Ltd.
- Applicants: Kinki University; Kobayashi Pharmaceutical Co., Ltd.
- Inventors: Shozo NISHIDA; Masanobu TSUBAKI; Tomoya TAKEDA; Kiyotaka OKUNO; Satoshi WACHI
- Web page: https://patentgrep.com/patent/US20210275616A1

## CPC

- A61K 36/07: Basidiomycota, e.g. Cryptococcus
- A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21)
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/12: Aerosols; Foams {(A61K9/0043, A61K9/0056, A61K9/006, A61K9/0073 take precedence; spray-films A61K9/7015)}
- A61K 9/1605: {Excipients; Inactive ingredients}
- A61K 9/2004: {Excipients; Inactive ingredients}
- A61K 9/4841: {Filling excipients; Inactive ingredients}
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/381: having five-membered rings
- A61K 31/4748: forming part of bridged ring systems (strychnine A61K31/475; morphinan derivatives A61K31/485)
- A61K 31/4965: Non-condensed pyrazines
- A61K 33/243: Platinum; Compounds thereof
- A61P 25/02: for peripheral neuropathies
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

No drug has been available for treating a peripheral sensory neuropathy caused as a side effect by a drug, in particular, by an anticancer drug such as oxaliplatin. A composition for ameliorating peripheral sensory neuropathy, which is characterized by including a Lentinus edodes mycelium extract, ameliorates symptoms induced by the drug such as the anticancer drug, including numbness of extremities, a pain in extremities, a reduction in deep tendon reflection, a reduction in muscle force, allodynia, hyperalgesia, impaired finger fine movement, impaired walking, stumbling, falling, impaired flexion (being difficult or impossible to sit on one's heels, sit cross-legged, sit with one's legs out to one side, sit on a chair, or the like), or paralysis of extremities.

## Claims

### Claim 1

A method of ameliorating peripheral sensory neuropathy, comprising:
administering a composition including a Lentinus edodes mycelium extract to a patient having peripheral sensory neuropathy, thereby ameliorating the peripheral sensory neuropathy.

### Claim 2 (depends on 1)

The method of ameliorating peripheral sensory neuropathy according to claim 1, wherein the peripheral sensory neuropathy is induced after administration of an anticancer drug.

### Claim 3 (depends on 2)

The method of ameliorating peripheral sensory neuropathy according to claim 2, wherein the anticancer drug is at least one selected from a DNA replication inhibitor, a microtubule-stabilizing agent, a microtubule polymerization inhibitor, and a proteasome inhibitor.

### Claim 4 (depends on 2)

The method of ameliorating peripheral sensory neuropathy according to claim 2, wherein the anticancer drug is a platinum-based anticancer drug.

### Claim 5

A method of treating peripheral sensory neuropathy, comprising:
administering a medical composition including a Lentinus edodes mycelium extract to a patient having peripheral sensory neuropathy, thereby treating the peripheral sensory neuropathy.

### Claim 6

A method of ameliorating peripheral sensory neuropathy, comprising:
administering a processed food including a Lentinus edodes mycelium extract to a patient having peripheral sensory neuropathy, thereby ameliorating the peripheral sensory neuropathy.

### Claim 7 (depends on 3)

The method of ameliorating peripheral sensory neuropathy according to claim 3, wherein the DNA replication inhibitor is a platinum-based anticancer drug.

### Claim 8 (depends on 1)

The method of ameliorating peripheral sensory neuropathy according to claim 1, wherein the composition is administered orally.

### Claim 9 (depends on 1)

The method of ameliorating peripheral sensory neuropathy according to claim 1, wherein the patient is a human patient.
